Literature DB >> 7526910

Hormonal receptors, cell proliferation fraction (Ki-67) and c-erbB-2 amplification in breast cancer. Relationship between differentiation degree and axillary lymph node metastases.

J J Sirvent1, M Santafé, M T Salvadó, T Alvaro, A Raventós, J Palacios.   

Abstract

In view of the limitations of conventional prognostic factors such as differentiation degree, metastatic lymph nodes, hormonal receptors and others, especially when early lesions are found, additional new markers have been studied, such as gene amplification and cell proliferation index, in order to choose the appropriate treatment. Primary breast carcinoma tumors from 97 patients were examined for differentiation degree, metastatic lymph nodes, hormonal receptors, c-erbB-2 amplification and cell proliferation index (Ki-67). A negative relationship with hormonal receptors and c-erbB-2 amplification, Ki-67 and differentiation degree was found, whereas the relationship between c-erbB-2, Ki-67 and differentiation degree was positive. No relationship was found between these factors and metastatic lymph nodes. The concurrence of high cell proliferation index, c-erbB-2 amplification and negative hormonal receptor presence would indicate a subpopulation with a high risk of recurrence. But a larger survival study is necessary to correlate these factors with clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526910

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  2 in total

1.  Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.

Authors:  Tetsuya Tsujikawa; Yoshio Yoshida; Yasushi Kiyono; Tetsuji Kurokawa; Takashi Kudo; Yasuhisa Fujibayashi; Fumikazu Kotsuji; Hidehiko Okazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-18       Impact factor: 9.236

2.  Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors.

Authors:  Matthew E Hardee; Rose J Eapen; Zahid N Rabbani; Matthew R Dreher; Jeffrey Marks; Kimberly L Blackwell; Mark W Dewhirst
Journal:  Cancer Chemother Pharmacol       Date:  2008-03-26       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.